Praxis Precision Medicines (PRAX) Share-based Compensation (2019 - 2026)

Praxis Precision Medicines' Share-based Compensation history runs 8 years deep, the most recent figure standing at $12.9 million for Q1 2026.

• On a quarterly basis, Share-based Compensation changed N/A year-over-year to $12.9 million in Q1 2026; TTM through Mar 2026 was $46.9 million, a 430.8% increase from a year earlier, with the FY2025 full-year figure at $33.9 million, up 10919.81% from the prior year.
• Share-based Compensation declined to $12.9 million in Q1 2026 per PRAX's latest filing, from $32.7 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $32.7 million in Q4 2025 and bottomed at -$32.5 million in Q4 2024.
• The 5-year median for Share-based Compensation is $3.5 million (2024), against an average of $4.5 million.
• Across the five-year window, Share-based Compensation tumbled 437.62% in 2022 and soared 1243100.0% in 2024, its largest moves.
• Year by year, Share-based Compensation stood at -$22.0 million in 2022, then soared by 212.56% to $24.7 million in 2023, then slumped by 231.35% to -$32.5 million in 2024, then surged by 200.6% to $32.7 million in 2025, then sank by 60.45% to $12.9 million in 2026.
• Per Business Quant, the three latest PRAX Share-based Compensation figures stand at $12.9 million (Q1 2026), $32.7 million (Q4 2025), and $52000.0 (Q3 2025).